CD27 is required for protective lytic EBV antigen–specific CD8+ T-cell expansion

Author:

Deng Yun1ORCID,Chatterjee Bithi1,Zens Kyra12ORCID,Zdimerova Hana1,Müller Anne1ORCID,Schuhmachers Patrick1ORCID,Ligeon Laure-Anne1,Bongiovanni Antonino34ORCID,Capaul Riccarda5,Zbinden Andrea5,Holler Angelika6,Stauss Hans6,Hammerschmidt Wolfgang7ORCID,Münz Christian1ORCID

Affiliation:

1. Viral Immunobiology, Institute of Experimental Immunology, and

2. Institute of Epidemiology, Biostatistics and Prevention, University of Zurich, Zurich, Switzerland;

3. Cellular Microbiology of Infectious Pathogens Group, Center for Infection and Immunity of Lille, and

4. BioImaging Center Lille-Nord de France, Institut Pasteur de Lille, Lille, France;

5. Institute of Medical Virology, University of Zurich, Zurich, Switzerland;

6. Institute of Immunity and Transplantation, Royal Free Campus, University College London, London, United Kingdom; and

7. Research Unit Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health and German Center for Infection Research, Munich, Germany

Abstract

Abstract Primary immunodeficiencies in the costimulatory molecule CD27 and its ligand, CD70, predispose for pathologies of uncontrolled Epstein-Barr virus (EBV) infection in nearly all affected patients. We demonstrate that both depletion of CD27+ cells and antibody blocking of CD27 interaction with CD70 cause uncontrolled EBV infection in mice with reconstituted human immune system components. While overall CD8+ T-cell expansion and composition are unaltered after antibody blocking of CD27, only some EBV-specific CD8+ T-cell responses, exemplified by early lytic EBV antigen BMLF1-specific CD8+ T cells, are inhibited in their proliferation and killing of EBV-transformed B cells. This suggests that CD27 is not required for all CD8+ T-cell expansions and cytotoxicity but is required for a subset of CD8+ T-cell responses that protect us from EBV pathology.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3